The rationale for the 1992 changes in the Food and Drug Administration regulations to permit accelerated approval of drugs for the treatment of life-threatening or severely debilitating disease was:
A. to allow for marketing before completion of Phase II of drug trials.
B. to ensure that the unknown risks associated with early approval are balanced by the need for effective drugs.
C. to change the rules because existing FDA regulations were too stringent for potentially effective drugs.
D. to accelerate approval of new drugs to give physicians the option of using them without research findings.
B
You might also like to view...
The nurse is providing care to a patient on fibrinolytic therapy. Which statement from the patient warrants further assessment and intervention by the critical care nurse?
a. "My back is killing me!" b. "There is blood on my toothbrush!" c. "Look at the bruises on my arms!" d. "My arm is bleeding where my IV is!"
The nurse anticipates that drug therapy for an acute severe attack of multiple sclerosis (MS) will be:
a. intravenous methylprednisolone. b. intramuscular injections of interferon be-ta-1b. c. massive doses of antibiotics. d. muscle relaxants and opioids.
The nurse is caring for a patient who recently had abdominal surgery. Which assessment finding requires the nurse's immediate attention?
a. Bruising near the surgical incision site b. Report of constipation c. Abdominal pain of 4/10 d. Urine output of 20 mL in the last hour
A patient is recovering from a bronchoscopy. What care should the nurse provide to this patient? Select all that apply.
A. Instruct the patient on use of incentive spirometry to use following the procedure. B. Report dark blood-tinged respiratory secretions to the physician. C. Instruct the patient to avoid eating and drinking until the gag reflex returns. D. Administer pain medications immediately following the procedure. E. Notify the physician with any breathing difficulty.